US20010023294A1 - New process for the preparation of isoindoline - Google Patents
New process for the preparation of isoindoline Download PDFInfo
- Publication number
- US20010023294A1 US20010023294A1 US09/785,956 US78595601A US2001023294A1 US 20010023294 A1 US20010023294 A1 US 20010023294A1 US 78595601 A US78595601 A US 78595601A US 2001023294 A1 US2001023294 A1 US 2001023294A1
- Authority
- US
- United States
- Prior art keywords
- isoindoline
- process according
- tetrahydrofuran
- preparation
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title description 9
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 10
- XQZYPMVTSDWCCE-UHFFFAOYSA-N phthalonitrile Chemical compound N#CC1=CC=CC=C1C#N XQZYPMVTSDWCCE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920006391 phthalonitrile polymer Polymers 0.000 claims abstract description 8
- 150000004677 hydrates Chemical class 0.000 claims abstract description 4
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 5
- CJAAPVQEZPAQNI-UHFFFAOYSA-N (2-methylphenyl)methanamine Chemical compound CC1=CC=CC=C1CN CJAAPVQEZPAQNI-UHFFFAOYSA-N 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- NOVIRODZMIZUPA-UHFFFAOYSA-N 2,3-dihydro-1h-isoindole;hydrochloride Chemical compound Cl.C1=CC=C2CNCC2=C1 NOVIRODZMIZUPA-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- -1 o-chloromethyl-benzylamine compound Chemical class 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KGKAYWMGPDWLQZ-UHFFFAOYSA-N 1,2-bis(bromomethyl)benzene Chemical group BrCC1=CC=CC=C1CBr KGKAYWMGPDWLQZ-UHFFFAOYSA-N 0.000 description 1
- AIIANTJFNUYXLB-UHFFFAOYSA-N 2,3-dihydro-1H-isoindole oxolane Chemical compound O1CCCC1.C1NCC2=CC=CC=C12 AIIANTJFNUYXLB-UHFFFAOYSA-N 0.000 description 1
- UXAHJGMSKTZEMJ-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyl-1,3-dihydroisoindole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CC2=CC=CC=C2C1 UXAHJGMSKTZEMJ-UHFFFAOYSA-N 0.000 description 1
- GODGXZRKRCLIBI-MLBSPLJJSA-N II.O=C1C/C(=C\C2=CC=CC=C2)C(=O)O1 Chemical compound II.O=C1C/C(=C\C2=CC=CC=C2)C(=O)O1 GODGXZRKRCLIBI-MLBSPLJJSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WHRPHGQMEZWMNF-RMKNXTFCSA-N O=C(C/C1=C\c2ccccc2)OC1=O Chemical compound O=C(C/C1=C\c2ccccc2)OC1=O WHRPHGQMEZWMNF-RMKNXTFCSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- ZXVXJGMFEGAQEI-YVLHZVERSA-N [H]C12CCCCC1([H])CN(C(=O)C/C(=C/C1=CC=CC=C1)C(=O)O)C2 Chemical compound [H]C12CCCCC1([H])CN(C(=O)C/C(=C/C1=CC=CC=C1)C(=O)O)C2 ZXVXJGMFEGAQEI-YVLHZVERSA-N 0.000 description 1
- WPGGHFDDFPHPOB-UHFFFAOYSA-N [H]C12CCCCC1([H])CN(C(=O)CC(CC1=CC=CC=C1)C(=O)O)C2 Chemical compound [H]C12CCCCC1([H])CN(C(=O)CC(CC1=CC=CC=C1)C(=O)O)C2 WPGGHFDDFPHPOB-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 239000011982 enantioselective catalyst Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001462 lacrimogenic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- Isoindoline is a synthesis intermediate that is widely used, especially in the preparation of pharmaceutical active ingredients.
- isoindoline is an important intermediate in the synthesis of 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric acid of formula (I):
- the compound of formula (I), and its addition salts and hydrates have especially valuable pharmacological properties. They are very powerful insulin secretors, which makes them useful in the treatment of non-insulin-dependent diabetes.
- the compound of formula (I), its preparation and its therapeutic use have been described in Patent Specification EP 0 507 534. Its industrial preparation is described in Patent Specification WO 99/01430. Given the pharmaceutical value of this compound, it was important to be able to obtain the intermediate isoindoline using a high-performance industrial synthesis process.
- Patent Specifications FR 1 577 845 and FR 1 578 582 describe the preparation of isoindoline by reacting ⁇ , ⁇ ′-dichlorobenzene with hexamethylenetetraamine, followed by treatment of the resulting ammonium salt in an HCl or SO 2 medium, and then cyclisation of the resulting o-chloromethyl-benzylamine compound in a basic medium. That method is especially lengthy and does not enable isoindoline to be obtained with a satisfactory yield.
- That process has several disadvantages. It has not been possible to reproduce the stated yields (91 to 98%). After removal of the catalyst by filtration and removal of the solvent by distillation, it has not been possible to distill off any compound from the medium heated to 120° C. in vacuo at 20 mbars. Moreover, in the case of industrial-scale processing the presence of ammonia in the reaction mixture requires a special installation in order to protect the environment.
- isoindoline as an intermediate in the synthesis of pharmaceutical active ingredients, especially 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid, and given the absence of a process that enables it to be obtained with a good yield and satisfactory purity, starting from inexpensive starting materials but avoiding the use of ammonia, the Applicant carried out in-depth research, which resulted in the development of a new process for the preparation of isoindoline.
- This process enables isoindoline to be obtained in a single step, by simple catalytic hydrogenation of phthalonitrile, a commercial product, without the addition of ammonia, with a yield of more than 75% and with very good purity.
- the catalyst used is 5% Pt/C.
- Pt/C enabled isoindoline to be obtained within a reasonable reaction time
- the amount of Pt/C used is from 10 to 25%, preferably 20%, of the weight of the phthalonitrile.
- the solvent used is tetrahydrofuran, a mixture of tetrahydrofuran/-water in which the water content is less than 10%, preferably less than 5%, or dimethoxyethane.
- tetrahydrofuran used on its own or in the presence of a limited amount of water
- dimethoxyethane enabled a satisfactory conversion rate to be obtained (Table 2).
- the hydrogen pressure inside the reactor is from 100 to 180 bars and preferably from 150 to 180 bars.
- the temperature of the reaction mixture is from 30 to 100° C. and preferably from 50 to 70° C.
- the isoindoline obtained under those conditions can then readily be isolated from its reaction medium by distillation, and then purified by precipitation in the form of a hydrochloride from a solvent, such as, for example, ethanol or ethyl acetate.
- a solvent such as, for example, ethanol or ethyl acetate.
- the isoindoline hydrochloride so obtained has very good purity and contains, for example, less than 1.5%, preferably less than 0.2%, of 2-methylbenzylamine, which makes its use especially advantageous in the synthesis of active ingredients, such as the compound of formula (I).
- the purity of the compounds was determined by gas-phase chromatography over an OPTIMA-5 amine column (Macherey-Nagel), using FID detection (flame ionisation) at 280° C.
- the reaction was carried out in an autoclave. 20 g of 5% platinum on carbon are added to 100 g of phthalonitrile dissolved in tetrahydrofuran. After purging with nitrogen, the mixture is heated at 60° C. and a hydrogen pressure of 180 bars is applied for 5 to 6 hours. After decompression and purging with nitrogen, the catalyst is removed by filtration. The tetrahydrofuran is distilled off from the filtrate at atmospheric pressure, and then isoindoline is in turn distilled off from the residue under a vacuum of 23 mbars. at a temperature of 100° C.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
- Isoindoline is a synthesis intermediate that is widely used, especially in the preparation of pharmaceutical active ingredients.
-
- its pharmaceutically acceptable salts and its hydrates.
- The compound of formula (I), and its addition salts and hydrates, have especially valuable pharmacological properties. They are very powerful insulin secretors, which makes them useful in the treatment of non-insulin-dependent diabetes. The compound of formula (I), its preparation and its therapeutic use have been described in Patent Specification EP 0 507 534. Its industrial preparation is described in Patent Specification WO 99/01430. Given the pharmaceutical value of this compound, it was important to be able to obtain the intermediate isoindoline using a high-performance industrial synthesis process.
- A number of methods for the preparation of isoindoline are already known. No process described in the literature, however, enables isoindoline to be obtained with satisfactory purity and yield, whilst still being readily transposable to an industrial scale and advantageous from the point of view of profitability.
- The preparation of isoindoline by the electrolytic or chemical reduction of phthalimide is described in the journals Bull. Soc. Chim. France 1956, 906-910, J. Pharm. Sci. 1964, 53 (8), 981 and J. Org. Chem. 1988, 53 (22), 5381-5383.
- Those processes do not, however, enable isoindoline to be obtained in a yield of more than 50%.
- The preparation of isoindoline by cyclising α,α′-dibromo-xylene in the presence of p-toluenesulphonylamine, followed by deprotection of the resulting N-(p-toluenesulphonyl)-isoindoline is described in the journals J. Org. Chem. 1957, 22, 1255-6 and Org. Synth. Collect. Vol. V, 406-408 and 1064-1066. That method, in addition to its low yield (less than 50%), has the disadvantage of using a highly lacrimogenic starting material.
- Patent Specifications FR 1 577 845 and FR 1 578 582 describe the preparation of isoindoline by reacting α,α′-dichlorobenzene with hexamethylenetetraamine, followed by treatment of the resulting ammonium salt in an HCl or SO2 medium, and then cyclisation of the resulting o-chloromethyl-benzylamine compound in a basic medium. That method is especially lengthy and does not enable isoindoline to be obtained with a satisfactory yield.
- The journal Izvestia Eng. Ed. 1959, 1778-80, describes the synthesis of isoindoline by hydrogenation of phthalonitrile at 100-120 atm in a dioxane/ammonia mixture, in the presence of nickel or cobalt at 100° C.
- That process has several disadvantages. It has not been possible to reproduce the stated yields (91 to 98%). After removal of the catalyst by filtration and removal of the solvent by distillation, it has not been possible to distill off any compound from the medium heated to 120° C. in vacuo at 20 mbars. Moreover, in the case of industrial-scale processing the presence of ammonia in the reaction mixture requires a special installation in order to protect the environment.
- Given the value of isoindoline as an intermediate in the synthesis of pharmaceutical active ingredients, especially 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid, and given the absence of a process that enables it to be obtained with a good yield and satisfactory purity, starting from inexpensive starting materials but avoiding the use of ammonia, the Applicant carried out in-depth research, which resulted in the development of a new process for the preparation of isoindoline.
- This process enables isoindoline to be obtained in a single step, by simple catalytic hydrogenation of phthalonitrile, a commercial product, without the addition of ammonia, with a yield of more than 75% and with very good purity.
- In order to obtain that result, the following operating conditions must be applied:
- The catalyst used is 5% Pt/C. In fact, it became apparent, surprisingly, that of all the catalysts generally employed, only Pt/C enabled isoindoline to be obtained within a reasonable reaction time (Table 1).
- The amount of Pt/C used is from 10 to 25%, preferably 20%, of the weight of the phthalonitrile.
TABLE 1 Catalyst Hydrogenation time % isoindoline Pd/C 20 h 1 Raney Ni 20 h 0 Rh/C 20 h 0 Ru/C 20 h 0 Pt/C 6 h 89.9 - Reaction conditions: tetrahydrofuran, 20% by weight of catalyst, 60° C., 180 bars of hydrogen
- The solvent used is tetrahydrofuran, a mixture of tetrahydrofuran/-water in which the water content is less than 10%, preferably less than 5%, or dimethoxyethane. In fact, it became apparent, surprisingly, that only tetrahydrofuran (used on its own or in the presence of a limited amount of water) and dimethoxyethane enabled a satisfactory conversion rate to be obtained (Table 2).
TABLE 2 Solvent Hydrogenation time % isoindoline tetrahydrofuran 6 h 89.9 tetrahydrofuran/water 98/2 6 h 89.3 dimethoxyethane 9 h 86.2 dioxane 20 h 40 ethanol 20 h 49 dimethylformamide 20 h 0 - Reaction conditions: catalyst Pt/C (20% by weight), 60° C., 180 bars of hydrogen
- The hydrogen pressure inside the reactor is from 100 to 180 bars and preferably from 150 to 180 bars.
- The temperature of the reaction mixture is from 30 to 100° C. and preferably from 50 to 70° C.
- The isoindoline obtained under those conditions can then readily be isolated from its reaction medium by distillation, and then purified by precipitation in the form of a hydrochloride from a solvent, such as, for example, ethanol or ethyl acetate.
- The isoindoline hydrochloride so obtained has very good purity and contains, for example, less than 1.5%, preferably less than 0.2%, of 2-methylbenzylamine, which makes its use especially advantageous in the synthesis of active ingredients, such as the compound of formula (I).
-
-
- the catalytic hydrogenation of which in the presence of an asymmetric catalyst yields the compound of formula (I).
- The following Examples illustrate the invention but do not limit it in any way.
- The purity of the compounds was determined by gas-phase chromatography over an OPTIMA-5 amine column (Macherey-Nagel), using FID detection (flame ionisation) at 280° C.
- Isoindoline
- The reaction was carried out in an autoclave. 20 g of 5% platinum on carbon are added to 100 g of phthalonitrile dissolved in tetrahydrofuran. After purging with nitrogen, the mixture is heated at 60° C. and a hydrogen pressure of 180 bars is applied for 5 to 6 hours. After decompression and purging with nitrogen, the catalyst is removed by filtration. The tetrahydrofuran is distilled off from the filtrate at atmospheric pressure, and then isoindoline is in turn distilled off from the residue under a vacuum of 23 mbars. at a temperature of 100° C.
- Isoindoline is thus obtained with a yield of 75% and purity of 89%.
- Isoindoline Hydrochloride
- A solution of 2.5N hydrochloric acid in ethyl acetate is added to 69 g of isoindoline obtained in Example 1 dissolved in 458 ml of ethyl acetate. The resulting solid is recovered by filtration, washed with ethyl acetate and then dried in an oven. Isoindoline hydrochloride is thus obtained with a yield of 82% and a purity of 98.5% with less than 1.5% of 2-methylbenzylamine.
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0002383A FR2805535B1 (en) | 2000-02-25 | 2000-02-25 | NEW PROCESS FOR THE PREPARATION OF ISOINDOLINE |
FR0002383 | 2000-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010023294A1 true US20010023294A1 (en) | 2001-09-20 |
US6320058B2 US6320058B2 (en) | 2001-11-20 |
Family
ID=8847398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/785,956 Expired - Fee Related US6320058B2 (en) | 2000-02-25 | 2001-02-16 | Process for the preparation of isoindoline |
Country Status (23)
Country | Link |
---|---|
US (1) | US6320058B2 (en) |
EP (1) | EP1127876B1 (en) |
JP (1) | JP3545351B2 (en) |
KR (1) | KR100464183B1 (en) |
CN (1) | CN1197848C (en) |
AR (1) | AR027537A1 (en) |
AT (1) | ATE227707T1 (en) |
AU (1) | AU774807B2 (en) |
BR (1) | BR0100757A (en) |
CA (1) | CA2338899C (en) |
DE (1) | DE60100044T2 (en) |
DK (1) | DK1127876T3 (en) |
EA (1) | EA003515B1 (en) |
ES (1) | ES2187492T3 (en) |
FR (1) | FR2805535B1 (en) |
HK (1) | HK1040248B (en) |
HU (1) | HUP0100881A3 (en) |
NO (1) | NO318881B1 (en) |
NZ (1) | NZ510205A (en) |
PL (1) | PL346035A1 (en) |
PT (1) | PT1127876E (en) |
SI (1) | SI1127876T1 (en) |
ZA (1) | ZA200101529B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126930B2 (en) | 2012-01-06 | 2015-09-08 | Lonza Ltd. | Method for preparation of octahydrocyclopenta[c]pyrrole |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070062520A (en) * | 2004-08-16 | 2007-06-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Method for preparing isoindole derivatives |
CN1324010C (en) * | 2005-01-12 | 2007-07-04 | 江苏省药物研究所 | Preparation of miglitol |
CN100441570C (en) * | 2006-05-24 | 2008-12-10 | 严洁 | A kind of preparation and quality control method of mitiglinide calcium |
FR2967673B1 (en) * | 2010-11-24 | 2012-12-28 | Minakem | SYNTHESIS OF N-HETEROCYCLES BY REDUCTIVE ALKYLATION OF CYAN DERIVATIVES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2773902A (en) * | 1954-05-10 | 1956-12-11 | California Research Corp | Hydrogenation of phthalonitriles |
US4254059A (en) * | 1979-08-01 | 1981-03-03 | Allied Chemical Corporation | Process for hydrogenation of nitriles |
-
2000
- 2000-02-25 FR FR0002383A patent/FR2805535B1/en not_active Expired - Fee Related
-
2001
- 2001-02-16 US US09/785,956 patent/US6320058B2/en not_active Expired - Fee Related
- 2001-02-16 CA CA002338899A patent/CA2338899C/en not_active Expired - Fee Related
- 2001-02-19 JP JP2001041119A patent/JP3545351B2/en not_active Expired - Fee Related
- 2001-02-22 PL PL01346035A patent/PL346035A1/en not_active IP Right Cessation
- 2001-02-23 CN CNB011168773A patent/CN1197848C/en not_active Expired - Fee Related
- 2001-02-23 EP EP01400484A patent/EP1127876B1/en not_active Expired - Lifetime
- 2001-02-23 AT AT01400484T patent/ATE227707T1/en not_active IP Right Cessation
- 2001-02-23 DK DK01400484T patent/DK1127876T3/en active
- 2001-02-23 NO NO20010936A patent/NO318881B1/en not_active IP Right Cessation
- 2001-02-23 PT PT01400484T patent/PT1127876E/en unknown
- 2001-02-23 KR KR10-2001-0009248A patent/KR100464183B1/en not_active Expired - Fee Related
- 2001-02-23 BR BR0100757-2A patent/BR0100757A/en not_active Application Discontinuation
- 2001-02-23 SI SI200130006T patent/SI1127876T1/en unknown
- 2001-02-23 AU AU23237/01A patent/AU774807B2/en not_active Ceased
- 2001-02-23 AR ARP010100820A patent/AR027537A1/en active IP Right Grant
- 2001-02-23 ZA ZA200101529A patent/ZA200101529B/en unknown
- 2001-02-23 DE DE60100044T patent/DE60100044T2/en not_active Expired - Fee Related
- 2001-02-23 HU HU0100881A patent/HUP0100881A3/en unknown
- 2001-02-23 NZ NZ510205A patent/NZ510205A/en unknown
- 2001-02-23 ES ES01400484T patent/ES2187492T3/en not_active Expired - Lifetime
- 2001-02-26 EA EA200100179A patent/EA003515B1/en unknown
-
2002
- 2002-03-14 HK HK02101967.5A patent/HK1040248B/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126930B2 (en) | 2012-01-06 | 2015-09-08 | Lonza Ltd. | Method for preparation of octahydrocyclopenta[c]pyrrole |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002507222A (en) | Method for producing substituted perhydroisoindole | |
KR100704590B1 (en) | Novel Process for Making (+)-cis-sertraline | |
HU227474B1 (en) | Process for industrial scale production of high purity donepezil hydrochloride polymorph i. | |
US6320058B2 (en) | Process for the preparation of isoindoline | |
RU2181358C2 (en) | Method of synthesis of sertraline from chiral tetralone | |
EA007743B1 (en) | Process for synthesizing derivatives of 1,3,4,6-tetrahydro-2h-3-benzazepin-2-one | |
US7795438B2 (en) | Processes for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine and hydrochloride | |
JP2646907B2 (en) | Method for producing 6-amino-7-fluoro-2H-1,4-benzoxazin-3 (4H) -one | |
US20080275252A1 (en) | Atipamezole Hydrochloride Crystallization Method | |
MXPA01001921A (en) | New process for the preparation of isoindoline | |
US5571928A (en) | 4-amino-3-hydroxy-phthalimidine, and a process for the preparation thereof | |
US4910343A (en) | Nitroamines | |
US20040077550A1 (en) | Process for preparing distamycin derivatives | |
EP1899310B1 (en) | Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride | |
EP0056343B1 (en) | Process for the preparation of 4-aminobutyramide | |
US5284960A (en) | Process for the production of 5-chloroxindole | |
JP2795492B2 (en) | Method for producing indole or indole derivative | |
EP0330186A2 (en) | 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinone, process for its production and processes for producing 2-(1-alkenyl)-3-hydroxy-1,4-naphthoquinone and 2-alkyl-3-acyloxy-1,4-naphthoquinone by using it | |
CN117567260A (en) | A kind of synthesis method of hydroxyquinone | |
JP2996713B2 (en) | Process for producing 2,3-cyclohexenopyridine | |
CN114105961A (en) | Preparation method of IDO1 inhibitor (LY-3381916) | |
JP3267025B2 (en) | Method for producing N- (6-chloro-3-pyridylmethyl) -N-alkylamine | |
GB2202535A (en) | Process for the preparation of alpha -amino-and alpha -azido-n-acyl-2, 6- dimethylanilines | |
CA2448300A1 (en) | Process for preparing sertraline intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADIR ET COMPAGNIE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOUVIE, JEAN-CLAUDE;FUGIER, CLAUDE;LECOUVE, JEAN-PIERRE;REEL/FRAME:011718/0977 Effective date: 20010125 |
|
AS | Assignment |
Owner name: LES LABORATOIRES SERVIER, FRANCE Free format text: MERGER;ASSIGNOR:ADIR ET COMPAGNIE;REEL/FRAME:012475/0568 Effective date: 20010730 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: KISSEI PHARMACEUTICAL COMPANY LTD, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LES LABORATOIRES SERVIER;REEL/FRAME:018420/0334 Effective date: 20060310 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20131120 |